Large Diffusion of Severe Acute Respiratory Syndrome Coronavirus 2 After the Successive Epidemiological Waves, Including Omicron, in Guinea and Cameroon: Implications for Vaccine Strategies.
Cameroon
Guinea
SARS-CoV-2
population-based survey
seroprevalence
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
06
12
2022
accepted:
18
04
2023
medline:
8
5
2023
pubmed:
8
5
2023
entrez:
8
5
2023
Statut:
epublish
Résumé
We aimed to estimate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence among the general population in Conakry, Guinea and Yaounde, Cameroon after the coronavirus disease 2019 Omicron wave. We conducted population-based, age-stratified seroprevalence surveys in Conakry and Yaounde (May and June 2022). We collected demographic and epidemiologic information and dried blood spot samples that were tested for SARS-CoV-2 immunoglobulin G (IgG) antibodies using recombinant nucleocapsid and spike proteins with Luminex technology. Samples were obtained from 1386 and 1425 participants in Guinea and Cameroon, respectively. The overall age-standardized SARS-CoV-2 IgG seroprevalence against spike and nucleocapsid proteins was 71.57% (95% confidence interval [CI], 67.48%-75.33%) in Guinea and 74.71% (95% CI, 71.99%-77.25%) in Cameroon. Seroprevalence increased significantly with age categories. Female participants were more likely than male participants to be seropositive. The seroprevalence in unvaccinated participants was 69.6% (95% CI, 65.5%-73.41%) in Guinea and 74.8% (95% CI, 72.04%-77.38%) in Cameroon. In multivariate analysis, only age, sex, and education were independently associated with seropositivity. These findings show a high community transmission after the different epidemiological waves including Omicron, especially among people aged >40 years. In addition, our results suggest that the spread of SARS-CoV-2 has been underestimated as a significant proportion of the population has already contracted the virus and that vaccine strategies should focus on vulnerable populations.
Sections du résumé
Background
UNASSIGNED
We aimed to estimate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence among the general population in Conakry, Guinea and Yaounde, Cameroon after the coronavirus disease 2019 Omicron wave.
Methods
UNASSIGNED
We conducted population-based, age-stratified seroprevalence surveys in Conakry and Yaounde (May and June 2022). We collected demographic and epidemiologic information and dried blood spot samples that were tested for SARS-CoV-2 immunoglobulin G (IgG) antibodies using recombinant nucleocapsid and spike proteins with Luminex technology.
Results
UNASSIGNED
Samples were obtained from 1386 and 1425 participants in Guinea and Cameroon, respectively. The overall age-standardized SARS-CoV-2 IgG seroprevalence against spike and nucleocapsid proteins was 71.57% (95% confidence interval [CI], 67.48%-75.33%) in Guinea and 74.71% (95% CI, 71.99%-77.25%) in Cameroon. Seroprevalence increased significantly with age categories. Female participants were more likely than male participants to be seropositive. The seroprevalence in unvaccinated participants was 69.6% (95% CI, 65.5%-73.41%) in Guinea and 74.8% (95% CI, 72.04%-77.38%) in Cameroon. In multivariate analysis, only age, sex, and education were independently associated with seropositivity.
Conclusions
UNASSIGNED
These findings show a high community transmission after the different epidemiological waves including Omicron, especially among people aged >40 years. In addition, our results suggest that the spread of SARS-CoV-2 has been underestimated as a significant proportion of the population has already contracted the virus and that vaccine strategies should focus on vulnerable populations.
Identifiants
pubmed: 37152188
doi: 10.1093/ofid/ofad216
pii: ofad216
pmc: PMC10157752
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofad216Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Conflict of interest. No reported conflicts of interest for all authors.
Références
Emerg Infect Dis. 2022 Jun;28(6):1233-1236
pubmed: 35470795
Open Forum Infect Dis. 2022 Mar 23;9(5):ofac152
pubmed: 35493112
PLoS One. 2021 Dec 17;16(12):e0260989
pubmed: 34919545
J Hum Hypertens. 2016 Apr;30(4):237-44
pubmed: 26310186
BMJ Glob Health. 2022 Aug;7(8):
pubmed: 35998978
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
EClinicalMedicine. 2021 Nov;41:101172
pubmed: 34723165
Lancet Glob Health. 2021 Jun;9(6):e773-e781
pubmed: 33711262
Clin Infect Dis. 2022 Mar 9;74(5):882-890
pubmed: 34089598
Cell. 2022 Oct 13;185(21):3992-4007.e16
pubmed: 36198317
Nat Hum Behav. 2021 Jul;5(7):947-953
pubmed: 33972767
Clin Infect Dis. 2021 Aug 2;73(3):e699-e709
pubmed: 33400782
Medicine (Baltimore). 2022 May 13;101(19):e29165
pubmed: 35583528
Lancet. 2022 Apr 2;399(10332):1303-1312
pubmed: 35305296
Nat Microbiol. 2022 Nov;7(11):1756-1761
pubmed: 36195753
Science. 2022 Oct 7;378(6615):eabq5358
pubmed: 36108049
Diagnostics (Basel). 2020 Jul 04;10(7):
pubmed: 32635444
N Engl J Med. 2022 Apr 7;386(14):1314-1326
pubmed: 35196424
J Clin Virol. 2020 Aug;129:104521
pubmed: 32623350
Lancet. 2022 Jan 29;399(10323):437-446
pubmed: 35065011
Lancet Glob Health. 2021 May;9(5):e588-e589
pubmed: 33609481
Clin Infect Dis. 2022 Mar 23;74(6):1030-1038
pubmed: 34185847